302 related articles for article (PubMed ID: 28817342)
21. Open-label, randomized study comparing basal insulin peglispro and insulin glargine, in combination with oral antihyperglycemic medications, in insulin-naïve Asian patients with type 2 diabetes.
Hirose T; Cai Z; Yeo KP; Imori M; Ohwaki K; Imaoka T
J Diabetes Investig; 2018 Jan; 9(1):100-107. PubMed ID: 28371567
[TBL] [Abstract][Full Text] [Related]
22. Quantification of Basal Insulin Peglispro and Human Insulin in Adipose Tissue Interstitial Fluid by Open-Flow Microperfusion.
Tiffner K; Boulgaropoulos B; Höfferer C; Birngruber T; Porksen N; Linnebjerg H; Garhyan P; Lam ECQ; Knadler MP; Pieber TR; Sinner F
Diabetes Technol Ther; 2017 May; 19(5):305-314. PubMed ID: 28328234
[TBL] [Abstract][Full Text] [Related]
23. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.
Bergenstal RM; Rosenstock J; Arakaki RF; Prince MJ; Qu Y; Sinha VP; Howey DC; Jacober SJ
Diabetes Care; 2012 Nov; 35(11):2140-7. PubMed ID: 22787177
[TBL] [Abstract][Full Text] [Related]
24. Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study.
Garg S; Selam JL; Bhargava A; Schloot N; Luo J; Zhang Q; Jacobson JG; Hoogwerf BJ
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():43-49. PubMed ID: 27393722
[TBL] [Abstract][Full Text] [Related]
25. Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine.
Bergenstal RM; Rosenstock J; Bastyr EJ; Prince MJ; Qu Y; Jacober SJ
Diabetes Care; 2014; 37(3):659-65. PubMed ID: 24198302
[TBL] [Abstract][Full Text] [Related]
26. Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D.
Blevins T; Zhang Q; Frias JP; Jinnouchi H; Chang AM;
Diabetes Care; 2020 Dec; 43(12):2991-2998. PubMed ID: 32616612
[TBL] [Abstract][Full Text] [Related]
27. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
Rosenstock J; Frías JP; Rodbard HW; Tofé S; Sears E; Huh R; Fernández Landó L; Patel H
JAMA; 2023 Nov; 330(17):1631-1640. PubMed ID: 37786396
[TBL] [Abstract][Full Text] [Related]
28. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.
Bolli GB; Riddle MC; Bergenstal RM; Wardecki M; Goyeau H; Home PD;
Diabetes Metab; 2017 Sep; 43(4):351-358. PubMed ID: 28622950
[TBL] [Abstract][Full Text] [Related]
29. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.
Jendle J; Testa MA; Martin S; Jiang H; Milicevic Z
Diabetes Obes Metab; 2016 Oct; 18(10):999-1005. PubMed ID: 27279266
[TBL] [Abstract][Full Text] [Related]
30. A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulin.
Manner DH; Luo J; Qu Y; Berry S; Gaydos BL; Jacober SJ
Diabetes Technol Ther; 2014 Aug; 16(8):499-505. PubMed ID: 24825416
[TBL] [Abstract][Full Text] [Related]
31. Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension).
Terauchi Y; Koyama M; Cheng X; Sumi M; Riddle MC; Bolli GB; Hirose T;
Diabetes Metab; 2017 Oct; 43(5):446-452. PubMed ID: 28433560
[TBL] [Abstract][Full Text] [Related]
32. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H
Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751
[TBL] [Abstract][Full Text] [Related]
33. Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes.
Jovanovič L; Peters AL; Jiang HH; Hardin DS
Aging Clin Exp Res; 2014 Apr; 26(2):115-21. PubMed ID: 24092662
[TBL] [Abstract][Full Text] [Related]
34. Effect of basal insulin dosage on blood glucose concentration in ambulatory surgery patients with type 2 diabetes.
Demma LJ; Carlson KT; Duggan EW; Morrow JG; Umpierrez G
J Clin Anesth; 2017 Feb; 36():184-188. PubMed ID: 28183563
[TBL] [Abstract][Full Text] [Related]
35. The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial.
de Lapertosa SB; Frechtel G; Hardy E; Sauque-Reyna L
Diabetes Res Clin Pract; 2016 Dec; 122():38-45. PubMed ID: 27776251
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study.
Blevins TC; Barve A; Sun B; Ankersen M
Diabetes Obes Metab; 2018 Aug; 20(8):1944-1950. PubMed ID: 29656504
[TBL] [Abstract][Full Text] [Related]
37. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.
DeVries JH; Bailey TS; Bhargava A; Gerety G; Gumprecht J; Heller S; Lane W; Wysham CH; Zinman B; Bak BA; Hachmann-Nielsen E; Philis-Tsimikas A
Diabetes Obes Metab; 2019 Mar; 21(3):622-630. PubMed ID: 30362250
[TBL] [Abstract][Full Text] [Related]
38. Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study.
Takeishi S; Tsuboi H; Takekoshi S
J Diabetes Investig; 2018 Jan; 9(1):91-99. PubMed ID: 28371461
[TBL] [Abstract][Full Text] [Related]
39. How much do I give? Dose estimation formulas for once-nightly insulin glargine and premeal insulin lispro in type 1 diabetes mellitus.
King AB; Clark D; Wolfe GS
Endocr Pract; 2012; 18(3):382-6. PubMed ID: 22440988
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Haahr PM; Lange M; Brown-Frandsen K; Moses A; Skibsted S; Kvist K; Buse JB;
N Engl J Med; 2017 Aug; 377(8):723-732. PubMed ID: 28605603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
